At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 333 enrolled
Drug / intervention
Dexmedetomidine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery
In Brief
A Phase 3 clinical trial evaluating Dexmedetomidine and Placebo for Pain. Completed, enrolled 333 participants across 4 sites.
Detailed Summary
The purpose of this study is to see if the drug, Dexmedetomidine (also known as Precedex), can reduce pain for patients having Thoracic Surgery and therefore reduce the amount of opioid drug needed after surgery. It is a drug that is already approved by the FDA (Food \& Drug Administration) for use as a sedative in hospitals and is currently used in the investigators Intensive Care Unit for this purpose. The investigators want to investigate if it also has pain relieving properties.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionDec 2022
TodayJul 2026
First PostedOct 31, 2013
Enrollment StartOct 1, 2013
Primary CompletionDec 22, 2022
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 12.7 years ago
Interventions
Dexmedetomidinedrug
Placebodrug